{
  "docId": "019de077-19d1-772e-933a-c7f1c42d9b04",
  "docSlug": "d223628377f56d072b5dbf426c21baf1",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 42,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a sidebar 'AT A GLANCE' to summarize key clinical development parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-19d1-772e-933a-c7f1c42d9b04/12",
  "deckHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04",
  "deckJsonHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04.json",
  "deckAnchorHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.87,
        "w": 0.29,
        "x": 0.71,
        "y": 0
      },
      "kind": "callout",
      "text": "AT A GLANCE\nMechanism of Action: ALK-selective tyrosine kinase inhibitor\nStage of Development: Global Phase 2 with registrational intent\nInitial Development Indication: ALK-positive NSCLC\nFDA Designations: Orphan Drug Designation",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eabe3ce2-2ae9-42e9-b514-e702e9de36e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.08,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "A brain-penetrant, selective inhibitor of ALK and ALK resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2eacb8c7-7178-47b3-b41e-5e252d2d41bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.39,
        "x": 0.08,
        "y": 0.46
      },
      "kind": "title",
      "text": "NVL-655 for ALK+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05d2da84-1a17-467f-87e2-dd74f8e5b4fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Aha! Moment",
      "slug": "aha-moment",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "b42e311e-e823-4a26-8912-252cbbbcea14",
      "evidence": "AT A GLANCE Mechanism of Action: ALK-selective tyrosine kinase inhibitor",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}